Gene

THBS2

thrombospondin 2

Explore in graph →CI-GENE-00035086HGNC:11786 ENSG00000186340 NCBI 7058 CIViC Cancer geneApproved

Curated evidence

Clinical evidence (1)

CIViC items involving this gene, grouped by molecular profile and therapy, with native levels and directions. 50 items per page.

civicCuratedShowing 1–1 of 1 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
THBS2 UNDEREXPRESSION1
(prognostic)	Malignant Colorectal NeoplasmCURATED_BROADER	Prognostic	B	Supports Poor Outcome	3	accepted	EID974 172 patients treated with neoadjuvant concurrent chemoradiotherapy (CCRT) were retrospectively analyzed for expression of thrombospondin 2 (THBS2) using IHC (discovery set with 46 rectal cancer patien… (full text at CIViC) PMID 26807188 · Lin et al., 2015 · Open in CIViC	civic

Cohorts

Alteration frequency by cohort (8)

Frequency = cases affected / cases profiled within one cohort. Cohorts are never pooled.

cbioportalObserved8 cohort rows · frequency = affected / profiled, as published by each cohort; cohorts are not pooled. Hover a row badge for its release.

Cohort	Mapped cancer	Alteration	Affected (n)	Profiled (n)	Frequency (%)	Rank in cohort	Source
Lung Cancer (SMC, Cancer Research 2016) lung_smc_2016	unmapped	Ssm	7	22	31.8%

Literature

Linked publications (1)

25 per page, newest first.

pubmedPublishedShowing 1–1 of 1 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

Low thrombospondin 2 expression is predictive of low tumor regression after neoadjuvant chemoradiotherapy in rectal cancer.
· Am J Transl Res · 2015 · PMID 26807188 · validated civic_curation pubmed